Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679513 | 1.00 | SIRT6 (0.48) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL2895340 | 0.92 | PDGFRB (0.50) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL29611567 | 0.89 | SIRT6 (0.45) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL13107196 | 0.89 | PDGFRB (0.51) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL18953141 | 0.89 | SIRT6 (0.45) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL11922558 | 0.89 | TDP1 (0.45) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL11991420 | 0.89 | PDGFRB (0.51) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL1560111 | 0.88 | PDGFRB (0.47) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL11922583 | 0.87 | TDP1 (0.50) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL20501210 | 0.87 | SIRT6 (0.44) | SIRT6PDGFRBFGFR1PDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| CN-118005766-B | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-118005766-A | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116751278-B | Preparation method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023245015-A2 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| WO-2007087717-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-09 | — | — | WO | disclosed |
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219176-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | SIRT6 1121/4885PDGFRB 1039/4885FGFR1 3121/4885 |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KRAS, NRAS, SOS1 | SIRT6 3532/4885PDGFRB 2663/4885FGFR1 1079/4885 |
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SIRT6 4215/4885PDGFRB 2939/4885FGFR1 1303/4885 |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | SIRT6 842/4885PDGFRB 1494/4885FGFR1 1305/4885 |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GOT2, HADH, CYP4A11 | SIRT6 2377/4885PDGFRB 4241/4885FGFR1 2590/4885 |
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | AADAC, DBI, ASNS | SIRT6 1405/4885PDGFRB 1557/4885FGFR1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.